ASPIRE: Potentially Slowing Lung Fibrosis in IPF
Trial Objectives
Idiopathic Pulmonary Fibrosis (IPF) is a progressive disease with few treatment options. Current treatments can slow the rate at which scar tissue builds up in the lungs, but can have major side effects. In the ASPIRE IPF clinical trial, researchers are examining whether an investigational medication called buloxibutid can slow down lung scarring and improve breathing.
Volunteers will be randomly assigned to receive either buloxibutid or a placebo (a medication containing no active ingredient). During clinic visits participants will receive physical exams and lung function tests and complete questionnaires. During the telephone or video calls, the trial team will monitor your health and wellbeing.
Who Can Participate
Adults 40 years or older diagnosed with IPF in the past 5 years. Participants must either be on a stable dose of nintedanib or not currently receiving treatment for IPF.
Age: 40+ Gender: Any
Estimated Time Commitment
8 clinic visits and 8 phone or video calls over approximately 62 weeks.
Payment & Reimbursement
Payment: Provided
Travel Reimbursement: Not Available
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
Vicore Pharma
Principal Investigators
Joshua J. Solomon, MD